Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Part 1, Part 2, Part 4 (Healthy subjects):~* Male subjects aged 18-55 years;~* Non smokers~* Lung function above 80% of predicted normal value~* Healthy subjects based on medical evaluation including medical history, physical examination, laboratory tests and cardiac testing~* ability to produce an adequate induced sputum sample (study part 4 only)~Part 3 (COPD patients):~* Males and females aged 40-75 years~* Current or past smokers~* stable patients with a post-bronchodilator FEV1 between 40 and 80% of predicted normal value and FEV1/FVC ratio \<0.7~* Ability to produce a spontaneous and an adequate induced sputum sample~Exclusion Criteria:~Parts 1,2, 4 (Healthy subjects):~* Any clinically relevant abnormalities and/or uncontrolled diseases~* Abnormal laboratory values~* Recent respiratory tract infection~* Hypersensitivity to the drug or excipients~* Positive serology results~* Positive cotinine, alcohol, drug of abuse tests~Part 3 (COPD patients):~* Females of childbearing potential~* History of asthma~* Unstable concomitant diseases~* Abnormal relevant Holter ECG parameters~* Recent acute exacerbations of COPD or respiratory tract infection~* Hypersensitivity to the drug or excipients~* Positive serology results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- CHF6297 Active (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).